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S U M M A R Y
Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) infections are responsible for longer
hospital stays, increased hospital costs, and poorer outcomes compared to methicillin-sensitive S. aureus
(MSSA) infections. We aimed to describe the epidemiology of S. aureus bacteraemia (SAB) and to
determine factors associated with MRSA infection in South Africa.
Methods: Cases of SAB were reported from September 2012 to September 2013 from three sentinel sites.
A case was deﬁned as the isolation of S. aureus from a blood culture during a 21-day period. Detailed
clinical information was collected. Multivariable logistic regression was done to determine factors
associated with MRSA infection and mortality.
Results: There were 442 cases of SAB reported; antimicrobial susceptibility testing was performed on
240 isolates (54%). Thirty-six percent (86/240) of cases had an MRSA infection. A longer hospital stay
before positive specimen collection (odds ratio (OR) 1.08, 95% conﬁdence interval (CI) 1.02–1.13,
p = 0.004), hospitalization in the last year (OR 15.7, 95% CI 2.5–99.5, p = 0.003), HIV infection (OR 4.9, 95%
CI 1.05–22.90, p = 0.044), and antibiotic use in the previous 2 months (OR 0.1, 95% CI 0.01–0.68,
p = 0.022) were independent predictors of MRSA. Older age, and in particular age 25–44 years (OR 22.2,
95% CI 2.7–185.5, p = 0.004, compared to those aged < 5 years), was the only independent predictor of
mortality amongst cases with SAB. MRSA isolates were non-susceptible to more antimicrobial agents
compared to MSSA isolates.
Conclusions: HIV infection was an independent risk factor for MRSA infection. The selection of
appropriate empirical antimicrobial treatment is essential in patients with MRSA infections because of
non-susceptibility to many other antimicrobial classes.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Staphylococcus aureus, a Gram-positive bacterium, can cause
bacteraemia, amongst a variety of other clinical syndromes. Due to* Corresponding author. Tel.: +27 11 386 6278; fax: +27 11 555 0430.
E-mail address: olgap@nicd.ac.za (O. Perovic).
http://dx.doi.org/10.1016/j.ijid.2014.10.011
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).metastatic complications, S. aureus bacteraemia (SAB) is strongly
associated with a higher mortality compared to other bacterial
bloodstream infections.1 In a Canadian study, the mortality rate of
SAB was 4–6 deaths per 100 000 persons.2 The incidence of SAB and
methicillin-resistant S. aureus (MRSA) bacteraemia has increased in
the USA3 due to increases in the number of invasive surgeries, use of
intravascular devices, and patients with immunodeﬁciencies.4
However, in the UK, a decline has been seen in MRSA incidence.5ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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documented. The prevalence of MRSA bacteraemia varies
greatly between African countries, with prevalence as high as
52% in Egypt, 45% in Algeria, 44% in Botswana,6 and 19% in
Morocco.7 Even in South Africa, the prevalence of MRSA
bacteraemia varies depending on the geographical location
and population studied.8–11
Numerous reports from various countries have shown that
MRSA bacteraemia results in a higher mortality compared to
methicillin-sensitive S. aureus (MSSA) bacteraemia.12–16 Crude
mortality rates for MRSA infection vary from 29%15 to 63%.13
Mortality rates vary depending on how mortality is deﬁned, the
study population, location, and medical practices. MRSA is also
more likely to be resistant to multiple antimicrobial agents
compared to MSSA17 and increases the length of hospital stay and
costs.12 Therefore it is important to determine risk factors that are
associated with MRSA infection to assist clinicians in reducing
MRSA infections and choosing appropriate empirical therapy.
The aim of this study was to describe the epidemiology of SAB
and to determine factors associated with MRSA infection at three
sentinel sites in Gauteng Province, South Africa.
2. Methods
2.1. Setting
Enhanced surveillance of SAB was initiated in September
2012. Three public sector sentinel sites in South Africa were
involved in the surveillance: Charlotte Maxeke Johannesburg
Academic hospital (CMJAH), a 1088-bed tertiary institution, Steve
Biko Academic (tertiary) and Tshwane (district) hospitals (SBAH/
TSH) with 832 and 197 beds, respectively, and Helen Joseph
Hospital (HJH), a tertiary hospital with 700 beds. All of these
hospitals are associated with universities and serve an urban
population. These hospitals provide care to patients in the city of
Johannesburg (approximate population 4.5 million) and the city of
Tshwane (approximate population 3 million).
2.2. Study design
A cross-sectional study was conducted from September 2012 to
September 2013. Surveillance ofﬁcers collected demographic and
clinical information through an interview and/or medical record
review on a standardized case report form (CRF). Data on the following
predisposing conditions were collected: chronic lung disease, chronic
renal disease, diabetes mellitus, cardiac disease, cerebrovascular
disease, malignancies, immunotherapy, previous surgery, aplastic
anaemia, organ transplant, prematurity, decubitus ulcer, dementia,
and smoking. Informed consent was obtained. CRFs were sent to the
National Institute for Communicable Diseases (NICD), Johannesburg
where quality checking and data capture occurred. Audits were
performed quarterly to ensure complete case ascertainment.
2.3. Case deﬁnitions
A case of bacteraemia was deﬁned when S. aureus was isolated
from a blood culture. A positive blood culture for S. aureus obtained
21 days after the ﬁrst positive blood culture was considered a
new case of S. aureus. For cases with viable isolates, a case was
deﬁned as MRSA or MSSA depending on whether the S. aureus
isolate was non-susceptible (MRSA) or susceptible (MSSA) to
oxacillin and/or cefoxitin. A case was deﬁned as hospital-acquired
bacteraemia if the ﬁrst blood culture positive for S. aureus was
collected 3 days after hospital admission. Infection was deﬁned
as community-associated if the ﬁrst blood culture positive for
S. aureus was collected <3 days after hospital admission and didnot fall into the hospital-associated community-onset category.
Hospital-associated community-onset infection was deﬁned if the
ﬁrst blood culture for S. aureus was obtained <3 days after hospital
admission and the patient was hospitalized in the 90 days before
SAB and/or had received haemodialysis and/or was a resident in a
long-term care facility or nursing home. Acute severe illness was
deﬁned as a Pitt bacteraemia score of >4.18 Empirical treatment
was deﬁned as an antimicrobial agent started prior to or less than
3 days following specimen collection. Directed treatment was
deﬁned as any antimicrobial agent that was prescribed 3 days or
more after a positive specimen was collected. Appropriate
antimicrobial therapy was deﬁned as the receipt of any antimi-
crobial agents to which the organism was susceptible. Inappropri-
ate antimicrobial therapy was deﬁned if the patient received no
antimicrobial agents to which the organism was susceptible or if
no antimicrobial therapy was received.
2.4. Laboratory methods
Sentinel site laboratories performed initial identiﬁcation and
antimicrobial susceptibility testing. S. aureus isolates were submit-
ted on Dorset transport medium (Diagnostic Media Products,
Sandringham, South Africa) together with a laboratory report form
to the NICD. Vitek 2 (bioMe´rieux, Durham, NC, USA) was used to
conﬁrm the identity of the isolate. Susceptibility testing was done
using the MicroScan Walkaway system (Siemens Healthcare
Diagnostics Inc., West Sacramento, CA, USA) and Gram-positive
minimum inhibitory concentration (MIC) panel type 33. Two
different systems were used for identiﬁcation and antimicrobial
susceptibility testing to rationalize time and costs. MICs were
interpreted using Clinical and Laboratory Standards Institute
guidelines.19 Isolates not identiﬁed as S. aureus were excluded.
DNA was extracted from purity plates using a crude boiling
method. The isolates were re-suspended in Tris–ethylenediami-
netetraacetic acid buffer and boiled at 95 8C for 25 min.
Ampliﬁcation and detection of mecA and nuc genes was done by
multiplex real-time PCR using the LightCycler 480 II instrument
(Roche Diagnostics Ltd, Rotkreuz, Switzerland) and the LightCycler
480 Probes Master kit (Roche Diagnostics, IN, USA).20 For SCCmec
typing, MRSA isolates were typed by conventional multiplex PCR
using the Qiagen Multiplex PCR kit (Qiagen, Hilden, Germany). The
multiplex PCR included 10 loci. Therefore 10 primer sets were
used. These were obtained from a previously published study.20
2.5. Ethics
Approval was obtained from the Human Research Ethics
Committee (Medical) (HREC), University of Witwatersrand,
Johannesburg (protocol number M120632) and from the individ-
ual facilities.
2.6. Statistical analysis
Data were extracted from Microsoft Access and analysed in
Stata 12.0 (College Station, TX, USA). The average incidence of SAB
for the study period was calculated for each hospital. The number
of S. aureus cases for the study period was the numerator and the
number of admissions for the same period was the denominator.
Incidence was expressed as S. aureus cases per 1000 admissions.
The incidence of SAB was calculated using all cases (audit cases
included). The MRSA incidence was calculated using only the cases
where isolates were submitted to NICD, since susceptibility
information was not available for audit cases. A descriptive analysis
was performed comparing factors between MRSA and MSSA cases.
The Chi-square test and Mann–Whitney U-tests were performed on
categorical and non-parametric continuous data, respectively. A
p-value of <0.05 was deemed statistically signiﬁcant.
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data as the median and interquartile range (IQR). Meningitis and
bone and joint infection categories were collapsed within the
unspeciﬁed category due to small numbers. The hospital-
associated community-onset infection category was excluded
and only hospital-acquired and community-onset infection
categories were used for further analysis. Two univariate and
multivariable logistic regression models were performed. The ﬁrst
to determine factors associated with MRSA cases compared to
MSSA cases and the second to determine factors associated with
mortality in cases with SAB. Variables with a p-value of <0.2 were
selected from the univariate analysis to be evaluated in the
multivariable model. The multivariable model was built using a
backward selection technique. The log-likelihood test was used to
assess the signiﬁcance of factors included in the model. A log-
likelihood p-value of <0.05 was used for inclusion of a variable in
the ﬁnal model. The model’s ﬁt was tested using a Hosmer–
Lemeshow goodness-of-ﬁt test.
3. Results
During the 13-month study period, a total of 442 SAB cases
were reported; 241 (55%) cases had isolates submitted to theTable 1
Clinical characteristics of patients with MRSA and MSSA infectionsa
Characteristics 
Age, years, median (IQR) 
Male 
Site of infection
Bacteraemia without focus 
Lower respiratory tract infection 
Meningitis 
Skin/soft tissue infections 
Bone and joint infection 
Unspeciﬁedc
Predisposing factors
HIV-infected 
CD4 count, cells/ml, median (IQR) 
Any predisposing conditiond
Previous MRSA episode 
Previous hospitalization in last year 
Previous dialysis 
Previous CVC in situ 
Previous long-term facility resident 
Crowded facility 
Treatment
Antibiotic usage in previous 24 h 
Antibiotic usage in previous 2 months 
Antibiotic use during this admission 
Severity of illness
Hospital-acquired infectione
Hospital-associated community-onsetf
Community-acquiredg
Case-fatality rate 
Acute severe illnessh
Length of hospital stay, days, median (IQR) 
Length of hospital stay before positive specimen collection, days, median (IQR) 
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylo
a Due to missing data, the total number of cases for certain variables differs from N = 24
are expressed as frequencies unless a range is speciﬁed. The percentages for all of the data
continuous variables: age (MRSA 85, MSSA 152), CD4 count (MRSA 5, MSSA 10) in HIV
b A p-value of <0.05 was considered signiﬁcant.
c The site of infection was not speciﬁed.
d Predisposing conditions included chronic lung and renal disease, diabetes mellitu
cerebrovascular disease, previous surgery, immunosuppressive conditions such as orga
e Hospital-acquired infection was deﬁned as a positive blood culture collected 3 d
f Hospital-associated community-onset (HACO) infection was deﬁned as a positive blo
and/or a resident in a long-term or chronic care facility and/or a patient who had rece
g Community-onset infection was deﬁned as a positive blood culture collected <3 d
h Acute severe illness: Pitt bacteraemia score >4.antimicrobial resistance reference laboratory at NICD and
201 cases (45%) were detected by audit. There were 240 cases
with oxacillin susceptibility results; clinical information was
available for 140 (58%) of these. The total number of admissions
from September 2012 to September 2013 for CMJAH, HJH, and
SBAH/TSH were 58 324, 38 836, and 57 439, respectively. The
incidence of SAB was highest at CMJAH at 3.7 cases per
1000 admissions, followed by HJH at 2.7 cases per 1000 admissions
and SBAH/TSH at 1.9 cases per 1000 admissions. The proportion of
MRSA differed signiﬁcantly by hospital (p < 0.001). CMJAH had the
highest proportion of MRSA isolates (58%, 46/79), followed by
SBAH/TSH (26%, 20/77) and HJH (24%, 20/84). The overall
proportion of MRSA infection was 36% (86/240). The MRSA
incidence was the highest for CMJAH at 0.08 cases per 1000 admis-
sions, followed by HJH at 0.05 cases per 1000 admissions and
SBAH/TSH at 0.03 cases per 1000 admissions.
3.1. Demographics and clinical characteristics
Persons with MRSA and MSSA bacteraemia were of similar age
(Table 1). The greatest proportion of cases of SAB occurred in those
aged <5 years (MRSA 38% (32/85), MSSA 33% (50/152)), with cases
<1 year old accounting for 27% (23/85) and 25% (38/152) of MRSAMRSA (n = 86) MSSA (n = 154) p-Valueb
n (%) n (%)
29 (0.4–45) 32 (1–50) 0.232
48/84 (57%) 86/145 (59%) 0.748
27/51 (53%) 51/89 (57%) 0.054
12/51 (24%) 7/89 (8%)
2/51 (4%) 1/89 (1%)
4/51 (8%) 7/89 (8%)
0/51 (0%) 3/89 (3%)
6/51 (12%) 20/89 (22%)
14/33 (42%) 18/68 (26%) 0.106
47 (30–56) 200 (169–277) 0.037
36/49 (73%) 46/87 (53%) 0.018
2/49 (4%) 5/85 (6%) 0.652
17/48 (35%) 19/83 (23%) 0.122
2/48 (4%) 5/82 (6%) 0.638
14/50 (28%) 6/83 (7%) 0.001
3/50 (6%) 3/85 (4%) 0.501
3/48 (6%) 2/84 (2%) 0.263
17/49 (35%) 24/83 (29%) 0.488
16/45 (36%) 10/79 (13%) 0.003
47/51 (92%) 74/89 (83%) 0.134
27/38 (71%) 34/75 (45%) 0.028
2/38 (5%) 4/75 (5%)
9/38 (24%) 37/75 (49%)
24/51 (47%) 22/89 (25%) 0.005
1/27 (4%) 3/39 (8%) 0.504
38 (14–64) 19 (7–33) 0.037
13 (2–27) 1 (0–12) <0.001
coccus aureus; IQR, interquartile range; CVC, central catheter venous catheter.
0 (for age and sex) or N = 140 (other variables obtained from case report forms). Data
 are calculated using the total number of cases unless indicated otherwise. Totals for
-infected individuals, length of hospital stay (MRSA 38, MSSA 74).
s, malignancy, decubitus ulcer, prematurity, smoking, dementia, cardiac disease,
n transplant, immunosuppressive therapy, and aplastic anaemia.
ays after admission.
od culture collected <3 days after admission in a patient admitted <90 days before
ived haemodialysis.
ays after admission, not falling into the HACO category.
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higher among all cases of SAB.
The overall HIV prevalence was 32%: 42% among MRSA cases
compared to 27% among MSSA cases (p = 0.106). HIV status was
unknown for 39 cases, of whom 46% had an MRSA infection. Only
15 HIV-infected cases had a CD4 cell count available. Antiretroviral
treatment information was available for 29 of the 32 HIV-infected
SAB cases. Among HIV-infected MRSA and MSSA cases, there was
no difference in the proportion on antiretroviral treatment (67%,
8/12 and 65%, 11/17, respectively).
Sixty percent of all cases had one or more predisposing
conditions, of which surgery prior to specimen collection was the
most common in both MRSA and MSSA cases. Five cases diagnosed
with MSSA infection had a history of previous MRSA infection. The
presence of a central venous catheter (CVC) was strongly
associated with the length of hospital stay before a positive
specimen was collected (p < 0.001). Patients who did not have a
CVC in situ had a median length of stay before positive specimen
collection of 2 days (IQR 0–14) compared to 34 days (IQR12–63) for
patients who had an indwelling CVC. Compared to MSSA cases,
MRSA cases had a longer hospital stay before positive specimen
collection irrespective of the presence or absence of an indwelling
CVC (MRSA: CVC in situ, median 57 days (IQR 12–63), no CVC,
median 13 days (IQR 0–21); MSSA: CVC in situ, 26 days (IQR 16–
54), no CVC, 1 day (IQR 0–9)).
In more than half of MRSA (53%) and MSSA (57%) cases,
bacteraemia with no focus was diagnosed. Only six cases were
deﬁned with hospital-associated community-onset SAB. Five cases
were previously hospitalized <90 days before the SAB episode, of
whom two had also received haemodialysis, and one case had
received only haemodialysis. Very few cases had severe illness (Pitt
bacteraemia score >4). There was no difference in severity of
illness between MRSA and MSSA cases.
The following variables had >10% missing information: HIV
status (28%), length of hospital stay (20%), severity of illness (53%),
antibiotic use in the previous 2 months (11%), and hospital-
acquired infection (19%).
3.2. Antimicrobial susceptibility
Among S. aureus isolates, 36% were oxacillin non-susceptible
(86/240). Non-susceptibility to daptomycin and linezolid was not
detected in these isolates (Figure 1). Four isolates were vancomycin0
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Figure 1. Antimicrobial susceptibility by hospital, September 2012 to September
2013.
CMJAH, Charlotte Maxeke Johannesburg Academic Hospital; HJH, Helen Joseph
Hospital; SBAH/TSH, Steve Biko Academic and Tshwane District Hospitals; AMI,
amikacin; GEN, gentamicin; CIP, ciproﬂoxacin; CLI, clindamycin; ERY,
erythromycin; LIN, linezolid; TEI, teicoplanin; RIF, rifampin; OXA, oxacillin; COT,
co-trimoxazole; Q/D, quinupristin/dalfopristin; VAN, vancomycin; DAP,
daptomycin.and teicoplanin non-susceptible (MIC 16 mg/ml). Thirteen cases
(6%) had vancomycin at the susceptible breakpoint value MIC 2 mg/
ml (ﬁve isolates were MRSA and eight isolates MSSA). MRSA isolates
were more likely to be non-susceptible to other antibiotic classes
compared to MSSA isolates (Table 2).
3.3. Molecular data
SCCmec typing was performed on 82 isolates of which nine
were non-typeable. Among the MRSA isolates, the most common
SCCmec type was III at 56% (45/73), followed by SCCmec type IV at
29% (23/73). Only four isolates were SCCmec type II and no SCCmec
type I isolates were found.
3.4. Antimicrobial treatment
Eighty-six percent (121/140) of patients with SAB received one
or more antimicrobial agents (Table 1). Ninety-ﬁve cases received
empirical treatment and 42 cases received directed treatment. A
greater proportion of MSSA cases (95%, 55/58) received appropri-
ate empirical therapy compared to MRSA cases (57%, 21/37)
(p < 0.001). All MSSA cases (25/25) and 59% (10/17) of MRSA cases
received appropriate directed therapy (p < 0.001). Vancomycin
was given as empirical treatment in 31% (29/95) of patients with
SAB and 49% (18/37) of patients with MRSA. A greater proportion of
MRSA cases who did not receive vancomycin died (61%, 14/23)
compared to MRSA cases who received vancomycin (38%, 9/24)
(p = 0.018). Among MRSA cases who did not receive vancomycin
(n = 23), only three cases received an appropriate antimicrobial
agent. Vancomycin was started as directed treatment in 55%
(11/20) of MSSA cases; four cases only received vancomycin, one
case received concomitant antimicrobial agents (amikacin and
meropenem) to which the organism was not susceptible, and six
received concomitant antimicrobial agents to which the organism
was susceptible.
3.5. Factors associated with MRSA cases compared to MSSA cases
All the variables that were most strongly associated with MRSA
infection (p < 0.2) in the univariate analysis are presented in
Table 3. Age was kept in the multivariable model as a possible
confounder. The multivariable analysis showed that length of stay
before specimen collection, previous hospitalization in the last
year, antibiotic use in the previous 2 months, and HIV infection
were signiﬁcant predictors of the acquisition of MRSA infection
(Table 3). HIV infection and length of stay before specimen
collection (p = 0.389), HIV infection and previous hospitalizationTable 2
Antimicrobial resistance among cases with MRSA and MSSA bacteraemiaa
Antimicrobial agent MRSA n/N (%) MSSA n/N (%) p-Value
Amikacin 53/53 (100%) 93/101 (92%) 0.035
Gentamicin 77/86 (90%) 33/154 (21%) <0.001
Ciproﬂoxacin 78/86 (91%) 13/154 (8%) <0.001
Clindamycin 80/86 (93%) 10/154 (6%) <0.001
Erythromycin 81/86 (94%) 19/154 (12%) <0.001
Trimethoprim/sulfamethoxazole 66/86 (77%) 15/154 (10%) <0.001
Linezolid 0/81 (0%) 0/154 (0%) N/A
Teicoplanin 5/86 (6%) 0/154 (0%) 0.002
Rifampin 30/86 (35%) 9/154 (6%) <0.001
Quinupristin/dalfopristin 6/86 (7%) 0/154 (1%) 0.001
Vancomycin 4/86 (5%) 0/154 (0%) 0.002
Daptomycin 0/81 (0%) 0/154 (0%) N/A
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive
Staphylococcus aureus; N/A, Not applicable.
a Cases with intermediate resistance according to Clinical and Laboratory
Standards Institute guidelines were reported as resistant.
Table 3
Univariate and multivariable analysis of factors associated with MRSA compared to MSSA
Characteristics Univariate analysisa Multivariable analysisb
OR (95% CI) p-Value OR (95% CI) p-Value
Length of hospital stay before positive specimen collection, days 1.04 (1.02–1.07) 0.001 1.08 (1.02–1.13) 0.004
Previous CVC in situ (yes vs. no) 4.99 (1.77–14.05) 0.002
Antibiotic usage in previous 2 months (yes vs. no) 3.80 (1.55–9.38) 0.004 0.1 (0.01–0.68) 0.022
Hospital-acquired infectionc (vs. community-onset) 3.14 (1.33–7.43) 0.009
Any predisposing conditiond (yes vs. no) 2.47 (1.15–5.28) 0.020
HIV-infected (yes vs. no) 1.97 (0.77–5.04) 0.158 4.89 (1.05–22.90) 0.044
Previous hospitalization in the last year 1.85 (0.84–4.04) 0.124 15.74 (2.49–99.48) 0.003
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; OR, odds ratio; CI, conﬁdence interval; CVC, central venous catheter.
a Only the variables that had a p-value of <0.2 in the univariate analysis are shown in the table.
b A p-value of <0.05 is signiﬁcant in the multivariable analysis.
c Hospital-associated infection was deﬁned as a positive blood culture 3 days after admission.
d Predisposing conditions included chronic lung and renal disease, diabetes mellitus, malignancy, decubitus ulcer, prematurity, smoking, dementia, cardiac disease,
cerebrovascular disease, previous surgery, immunosuppressive conditions such as organ transplant, immunosuppressive therapy, and aplastic anaemia.
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2 months (p = 0.944), and age and HIV infection (p = 0.552) were
included as possible interaction terms in the model, but none was
signiﬁcant.
3.6. Factors associated with mortality in SAB cases
The factors associated with outcome are shown in Table 4. In
the unadjusted model, MRSA bacteraemia was signiﬁcantlyTable 4
Factors associated with outcome among cases with Staphylococcus aureus bacteraemia
Characteristic Died (n = 47), 
Age, years
<5 7 (15%) 
5–24 2 (4%) 
25–44 21 (45%) 
45–64 13 (28%) 
65 4 (9%) 
Sex
Male 26/46 (57%) 
Female 20/46 (43%) 
Methicillin-resistant infection
Yes 25 (53%) 
No 22 (47%) 
HIV-infected
Yes 16/35 (46%) 
No 19/35 (54%) 
Empirical therapy received
Appropriateb 25/34 (74%) 
Inappropriatec 9/34 (26%) 
Any predisposing conditiond
Yes 33/43 (77%) 
No 10/43 (23%) 
Time to antibiotic start, days, median (IQR) 1 (6 to 
Length of hospital stay before positive specimen
collection, days, median (IQR)
6 (0–20) 
Length of hospital stay, days, median (IQR) 18 (7–30) 
Previous CVC in situ
Yes 6/44 (14%) 
No 38/44 (86%) 
Origin of infection
Hospital-acquired infectione 21/33 (64%) 
Community-onset infectionf 12/33 (36%) 
IQR, interquartile range; CVC, central venous catheter.
a Due to missing data, the total number of cases for certain variables differs from the to
range is speciﬁed. The percentages for all of the data are calculated using the total num
b Appropriate empirical therapy: Antimicrobial agents that were started before or wi
organism.
c Inappropriate empirical therapy: Antimicrobial agents that were started before or wi
or no treatment was received.
d Predisposing conditions included chronic lung and renal disease, diabetes mellitu
cerebrovascular disease, previous surgery, immunosuppressive conditions such as orga
e Hospital-acquired infection was deﬁned as a positive blood culture collected 3 d
f Community-onset infection was deﬁned as a positive blood culture collected <3 dassociated with mortality (OR 2.8 95% CI 1.36–5.83, p = 0.005)
but did not remain signiﬁcant in the adjusted model (OR 3.7 95% CI
0.50–27.6, p = 0.197). The factors that were adjusted for were age,
having any predisposing conditions, length of hospital stay before
specimen collection, time to start of antibiotic treatment,
appropriate empirical therapy, HIV infection, and having a CVC
inserted previously. The only factor that was a signiﬁcant predictor
of mortality was older age, and in particular age 25–44 years (OR
22.2, 95% CI 2.7–185.5, p = 0.004).a
n (%) Survived (n = 94), n (%) p-Value
43 (46%) <0.001
14 (15%)
17 (18%)
17 (18%)
3 (3%)
48/86 (56%) 0.938
38/86 (44%)
27 (29%) 0.005
67 (71%)
16/66 (24%) 0.027
50/66 (76%)
51/61 (84%) 0.239
10/61 (16%)
49/93 (52%) 0.008
44/93 (47%)
1) 1 (1 to 1) 0.254
4 (0–14) 0.301
27 (10–46) 0.102
14/89 (16%) 0.751
75/89 (84%)
40/74 (54%) 0.355
34/74 (46%)
tal number of cases who died or survived. Data are expressed as frequencies unless a
ber of cases unless indicated otherwise.
thin 3 days of specimen collection of which one or more were effective against the
thin 3 days of specimen collection of which all were ineffective against the organism,
s, malignancy, decubitus ulcer, prematurity, smoking, dementia, cardiac disease,
n transplant, immunosuppressive therapy, and aplastic anaemia.
ays after admission.
ays after admission.
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To our knowledge this is the ﬁrst study in South Africa that has
prospectively collected detailed clinical information on patients
with SAB at multiple sites. MRSA and MSSA infection was most
common in the <5 years age group. Forty-nine percent of patients
with MRSA did not receive vancomycin. We also showed that HIV
infection, among other factors, was a risk factor for MRSA infection.
Age was the only predictor of mortality in cases with SAB when
controlled for other factors.
SAB incidence is hospital-speciﬁc. A study conducted in
Australia from 1999 to 2002 in 17 hospitals showed that SAB
incidence varied from 0.6 to 3.24 cases per 1000 admissions,
depending on the type of hospital.21 Similarly MRSA bacteraemia
rates varied from 0 to 0.89 cases per 1000 admissions between
hospitals. Our study showed that SAB and MRSA incidence varied
from 1.9 to 3.7 cases per 1000 admissions and 0.03 to 0.08 cases per
1000 admissions, respectively.
The proportion of patients with MRSA infection varies by
country. High MRSA rates of 52.4%, 48.4%, and 48.2% have been
reported from Malta, Portugal, and Cyprus.22 Very low MRSA
prevalence is found in Scandinavian countries, varying from 0% in
Iceland to 0.8% in Denmark. Our MRSA prevalence of 36% is
comparable to Ireland (38.1%), the UK (35.6%), and Israel (33.5%).
Despite the MRSA prevalence in our study being an underestima-
tion, susceptibility testing was done only on viable isolates sent to
the reference laboratory; the MRSA prevalence was found to be
higher than in a previous study conducted in two Gauteng
hospitals in South Africa from November 1999 to October 2002,
which showed an MRSA bacteraemia prevalence of 23%.8 Perovic
et al. only looked at adults, while our study focused on all ages. The
difference in MRSA prevalence among countries could be due to
differences in the types of hospitals involved in surveillance,
clinical co-morbidities of patients, infection control practices, and
medical practices. In South Africa, it is likely that the incidence of
MRSA bacteraemia is increasing in comparison with previous
South African publications, but a more in-depth trend analysis is
required to verify this.8
Risk factors for the acquisition of MRSA infection vary between
different studies depending on the study population. In studies
that have looked at cases of nosocomial SAB, previous hospitaliza-
tion, length of stay before positive blood culture, surgery, enteral
feeding, the use of intravascular catheters, and age have been
found to be independent risk factors for MRSA infection.23–26 A
study that looked at cases with SAB only found previous MRSA
infection or colonization to be a risk factor for MRSA infection.27
We showed similar risk factors for MRSA infection, with previous
hospitalization in the last year as the strongest predictor of MRSA
infection. In addition, our study showed that cases with HIV
infection had almost 5-times higher odds of developing an MRSA
infection compared to HIV-uninfected cases. HIV-infected patients
have a higher risk of MRSA colonization compared to HIV-
uninfected individuals (OR 3.3, 95% CI 1.3–14.7),28 which could
contribute to their higher odds of developing MRSA bacteraemia.
Among HIV-infected cases, a low CD4 cell count can increase the
risk of MRSA infection.29 We showed that among HIV-infected
cases, the median CD4 cell count was signiﬁcantly lower in cases
with MRSA compared to cases with MSSA. Other factors that could
increase the risk of MRSA in HIV-infected individuals are
nosocomial infection, prior antibiotic use, previous MRSA infec-
tion, and previous hospitalization.29,30 Earlier initiation of antire-
troviral therapy is important to prevent poor immune status and to
decrease the risk of MRSA infection.29
Compared to cases with MSSA infection, cases with MRSA
infection had a higher mortality rate. Reasons for a worse outcome
with MRSA could be due to SCCmec-associated virulence factors.31In addition, 49% of cases with MRSA were not treated with
vancomycin, of whom 62% died. Also, vancomycin is known to be
less effective in clearing the pathogen due to poor tissue
penetration and slower bactericidal activity, which is unrelated
to vancomycin MICs in the high susceptible range.32 Four MRSA
isolates had a vancomycin MIC of 16 mg/ml. However, reports
have shown that infection with heteroresistant vancomycin-
intermediate S. aureus (hVISA) is not associated with increased
mortality.33
MRSA infection was not a signiﬁcant predictor of death after we
controlled for possible confounders. There is conﬂicting evidence
regarding whether MRSA infection is a predictor of mortality.
Cosgrove et al. found that mortality was higher in patients with
MRSA than with MSSA (OR 1.93, 95% CI 1.54–2.42, p < 0.001),
which remained signiﬁcant after controlling for potential con-
founders such as age and severity of illness (OR 1.88, 95% CI 1.33–
2.69, p < 0.001).12 Other studies did not ﬁnd a higher mortality in
cases with MRSA infection compared to MSSA cases.23,24,27,34 Older
age was the only predictor of mortality among cases with SAB.
Interestingly, only the 25–44 years age group had a signiﬁcantly
higher odds of dying compared to the <5 years age group. Previous
reports have shown age to be a signiﬁcant predictor of mortality in
cases with SAB, especially age >65 years, or with every 10-year
increase in age.35,36 Our study had only seven cases aged 65
years, which could explain why, in the multivariable model, this
age group was not a signiﬁcant predictor of mortality. Even though
we accounted for HIV infection in the multivariable model, the 25–
44 years age group remained a signiﬁcant predictor of mortality,
probably because a large proportion (28%) of cases had an
unknown HIV status. HIV infected individuals in our study had a
worse outcome compared to HIV-uninfected individuals, regard-
less of oxacillin susceptibility: 50% (16/32) and 28% (19/69) died,
respectively (p = 0.027).
MRSA isolates were more likely to be resistant to other
antimicrobial classes compared to MSSA isolates. This limits the
antimicrobial choices when patients are treated empirically. Our
study looked at antimicrobial resistance patterns over a 13-month
period only, and we were unable to look at changes over time. A
study conducted by Marais et al. from August 2005 to November
2006 included 15 public and eight private hospitals across South
Africa and analysed antimicrobial resistance in MRSA isolates.17 In
comparison to this study, we found a higher prevalence of non-
susceptibility among MRSA isolates from only public sector
laboratories to amikacin (29% vs. 100%), gentamicin (86% vs.
90%), erythromycin (71% vs. 94%), clindamycin (17% vs. 93%) and
trimethoprim/sulfamethoxazole (71% vs. 77%). Only rifampin
resistance was lower in our study (53% vs. 35%). No vancomycin,
teicoplanin, or quinupristin/dalfopristin-resistant MRSA isolates
were found by Marais et al., whereas the prevalence of non-
susceptibility was 5–7% for these three antibiotics in our study.
Differences in antimicrobial non-susceptibility could be attributed
to the fact that our study included only four hospitals in Gauteng
Province, while that of Marais et al. included sites across all nine
provinces of South Africa. In addition, all of our MRSA isolates were
from blood cultures, whereas only 35.5% of isolates in the study by
Marais et al. were from blood.
Thirty-two percent of MRSA isolates had SCCmec type IV, which
is linked to community-associated infection. Sixty-nine percent of
SCCmec type IV MRSA isolates were obtained from blood cultures
collected 3 days after admission, which suggests that communi-
ty-associated MRSA strains are being transmitted in hospitals.
Similarly, a study from Switzerland found that 87% of hospital-
associated MRSA cases carried SCCmec type IV.37 It is important to
monitor community-associated MRSA because of greater toxin
production and tissue necrosis, which can cause higher mortality
rates compared to hospital-associated MRSA.38,39
M.C. Fortuin-de Smidt et al. / International Journal of Infectious Diseases 30 (2015) 41–48 47The limitations of our study were that very few HIV-infected
cases had a documented CD4 count, hence we could not control for
it in the multivariable analysis. More than 10% of information was
missing for HIV status, length of hospital stay, severity of illness,
and origin of infection, but the proportion was similar between
MRSA and MSSA cases (p > 0.05). Variable blood culture-taking
practices could underestimate the true burden of SAB. More than
50% of isolates from one hospital were not viable and susceptibility
testing could not be performed. A long hospital stay, a long lag
period in sending CRFs to the reference laboratory, and missing
hospital folders could have contributed to a large proportion of
cases without CRF information. Molecular information was only
available for a few isolates. The strength of the study is that
detailed clinical information was collected, particularly on
antibiotic usage, predisposing conditions, HIV status, and previous
hospitalizations among cases with SAB.
In conclusion, HIV infection was a signiﬁcant predictor of MRSA
infection. Being aged 25–44 years was signiﬁcantly associated with
mortality among cases with SAB. MRSA cases were infected with
isolates that were non-susceptible to multiple antibiotics. As a
public health measure, antimicrobial susceptibility surveillance
and antibiotic prescription practices should be monitored.
Knowledge of local epidemiology as well as factors predictive of
MRSA infection will assist in guiding the use of appropriate
empirical treatment.
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